The UroGen class action lawsuit seeks to represent purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, inclusive (the “Class Period”).  Captioned Cockrell v. UroGen Pharma Ltd., 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen and certain of UroGen’s top current and former executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the UroGen class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].

Lead plaintiff motions for the UroGen class action lawsuit must be filed with the court no later than July 28, 2025.

Read on to learn everything you need to know about the lead plaintiff process in the UroGen class action lawsuit.

The Lead Plaintiff Process in the UroGen Class Action Lawsuit

Under the Private Securities Litigation Reform Act of 1995 (PSLRA):

• Any investor who purchased and suffered losses in UroGen stock may seek appointment as lead plaintiff in the UroGen class action lawsuit.
• A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.
• A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit.
• The lead plaintiff can select a law firm of its choice to litigate the securities class action lawsuit.
• An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.

The Lead Plaintiff Deadline in the UroGen Class Action Lawsuit

​​Lead plaintiff motions for the UroGen class action lawsuit must be filed with the court no later than July 28, 2025. When a securities class action is filed, such as the UroGen class action lawsuit:

1. The person who files the first complaint is required to publish a notice announcing the filing.
2. Anyone who wants to be the lead plaintiff on behalf of the class must thereafter file a motion to be appointed as lead plaintiff(s) no later than 60 days after the notice was published.

The Benefits of Serving as a Lead Plaintiff in the UroGen Class Action Lawsuit

1. Negotiating more competitive attorney fees and reducing litigation costs.
2. Managing the litigation by overseeing the progress of the case and reviewing important filings.
3. Participating in mediation and settlement discussions.
4. Having a voice in decision-making processes regarding the settlement.
5. No financial risk, as lead counsel covers all costs and expenses and are paid only if they secure a settlement or judgment recovery for the class
6. Potentially enjoying long-term benefits from governance reform resulting from the litigation.

The Responsibilities the Lead Plaintiff Will Have in the UroGen Class Action Lawsuit

1. Selecting, monitoring, and overseeing Lead Counsel.​
2. Reviewing and commenting on court filings on behalf of the class.
3. Discussing litigation strategies with the Lead Counsel.
4. Attending depositions (if necessary) and giving a deposition.
5. Attending hearings (if necessary).
6. Participating in mediation and the trial (if necessary).
7. Provide input on any decision concerning the settlement of the securities class action.

The Eligibility Criteria for Lead Plaintiff Appointment in the UroGen Class Action Lawsuit

To be eligible for appointment as the lead plaintiff in the Red Cat Class Action Lawsuit, an investor must meet the following criteria:

1. Securities Acquisition: The investor must have purchased or acquired UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023, and May 15, 2025, inclusive.
2. Financial Losses: The investor must have suffered financial losses as a direct result of the alleged securities fraud perpetrated by UroGen and its executives.
3. Typicality and Adequacy: The investor’s legal claims must be typical of those asserted on behalf of the class, and they must demonstrate their ability to adequately represent the interests of the entire class through experience, resources, and the absence of conflicts of interest.

It is crucial to note that both domestic and international investors who meet these criteria are eligible to seek appointment as the lead plaintiff in the UroGen class action lawsuit, as courts have consistently recognized the rights of non-U.S. investors in securities class actions.

The Legal Requirements for Prevailing in the UroGen Class Action Lawsuit

1. Material Misrepresentation or Omission
2. Scienter
3. Connection to Securities Transaction
4. Reliance
5. Economic Loss
6. Loss Causation

You Cannot serve as a Lead Plaintiff in the UroGen Class Action Lawsuit If You Purchases Shares outside of the Class Period​​

Even if you suffered losses in UroGen stock, if you purchased securities outside of the Class period, you will not be able to participate in the UroGen class action lawsuit.

You Can Serve as a Lead Plaintiff In the UroGen Class Action Lawsuit if You Are Serving as a Lead Plaintiff In Another Securities Fraud Case

Unless you have been a lead plaintiff in more than five securities class actions during any three-year period which is expressly prohibited by the securities laws, with exceptions for institutional investors. Otherwise, if you suffered losses in Bumble stock, you may move to be appointed lead plaintiff in the UroGen class action lawsuit.